Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
Clinical trial NCT05925530 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05925530
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-22
- Primary completion
- 2026-01-12
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.